First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+ Metastatic Breast Cancer
First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+
Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer, according to an interim analysis of an open-label phase 3 randomized study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.Activity Objectives:
After participating in this educational activity, participants should be better able to:
- Identify patients whose tumors overexpress HER2 and who have received prior therapy, including EGFR- and HER2 receptor tyrosine kinases.
- Assess first-line treatment for patients with HER2+ metastatic breast cancer based on recently released randomized controlled trials.
Click Next to begin the activity.